Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Could Ultraviolet Light Technology Treat MS?

An ultraviolet chemical tool has been developed that has the ability to observe and control inflammation. It will allow scientists to study immune response and may one day work to treat inflammatory diseases while sparing healthy tissue. 

Researchers from Cornell University used chromatin-modifying enzymes including histone deacetylases (HDACs) in order to develop a strategy to regulate, observe, and control the HDAC inhibitors. The researchers added that immune cells like macrophages are mediated at the transcriptional level by these HDACs. The investigators additionally learned that the inhibitors can be selectively delivered to target cells by ultraviolet irradiation to minimize off-target effects, they wrote. 

The study authors described their approach in a Chemical Science paper saying, “the inhibitor is released in the vicinity of or within the activated macrophages to decrease inflammation through change in gene expression.” Other methods similar to this have been used to photocage HDAC inhibitors, the researchers explained, but their approach differs because it uses HDACs within live cells to influence their cellular behavior and function.

The researchers believe their strategy can be utilized in the treatment of many inflammatory diseases, adding that one of the benefits of their strategy is that it can avoid undesirable side effects such as immunosuppression of other tissues, potentially leading to infection. “We are pushing the forefront of developing new technologies to control inflammation and the immune system, with the ultimate goal of being able to study these biological pathways and perhaps develop therapies for inflammatory diseases,” first author Pamela Chang said in a press release. “If you turned off all the HDACs in the body, you would probably be hitting a lot of pathways that you didn’t want to turn off. We can control when and where we turn off the HDACs using light. The idea is that you can actually target the tissue that has chronic inflammation and regulate it by selectively inhibiting HDACs in the tissue that’s affected.” The researchers said their hope is that their method can be utilized to treat many disorders related to inflammation, including autoimmune diseases as well as cancer.  They continued that HDAC inhibitors like suberoylanilide hydroxamic acid (SAHA) – a competitive inhibitor or class I and II Zn2+ dependent HDACs that bind within the active site in the enzyme, according to the paper – have been well studied and are already approved by the US Food and Drug Administration. SAHA also contains anti inflammatory effects on multiple immune cell types, the study authors said. 

Because of this, they wrote, selectively delivering some of the ultraviolet activated HDAC inhibitors could bring about positive and desirable physiological outcomes.

“Treatment-wise, our tools could be used for targeted inhibition of inflammation,” Chang told MD Magazine in an email. “This [multiple sclerosis treatment] would be an interesting future direction, but first we will need to test in animal models of disease. I don’t think MS would be the best disease to try because it is systemic, but perhaps other diseases that have localized inflammation and would be accessible to UV light such as irritable bowel disease, allergy, and some cancers. The advantage of our approach is its targeted nature so that we can avoid off-target effects on healthy surrounding tissue.”

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length
Click here to read more

Go to Newer News Go to Older News